In VivoPIB PET Amyloid Imaging: Normals, MCI & Dementia

描述（由申请人提供）：使用新型正电子发射断层扫描（PET）示踪剂匹兹堡化合物-B（PIB）的第一项概念验证研究表明，PIB-PET成像检测到活体AD受试者大脑中的淀粉样蛋白沉积，其模式与尸检研究预测的模式相似。该提案的总体目标是在AD的早期阶段定义淀粉样蛋白沉积，并通过检查PIB保留和其他代谢和结构标记物来辅助表征PIB作为淀粉样蛋白沉积的替代标记物。这些研究提出了3个主要问题：1）在正常老年受试者、轻度认知障碍（MCI）受试者以及轻度、中度和重度阿尔茨海默病（AD）受试者中，PIB的沉积是否可检测到，并与总体认知或可与大脑特定区域的认知功能的严重程度定量相关？2)在一项纵向研究中，这些受试者是否会显示PIB潴留（β淀粉样蛋白的量）增加，在该研究中，每年进行一次PIB-PET和认知评估，持续长达三年？3)在帕金森病（PD）、PD伴痴呆（PDD）和路易体痴呆（DLB）的临床谱中，PIB潴留的患病率是多少;在这些患者中观察到的临床痴呆症状的基础是多少淀粉样蛋白沉积？我们还将进行氟脱氧葡萄糖PET（FDG-PET）和MRI，以关联代谢和体积数据、认知和PIB沉积。为了实现这些目标，我们建立了一个行政核心，以监督和协调项目，预算和数据传输;一个临床核心，以确定和评估来自匹兹堡大学ADRC和运动障碍诊所在神经科和匹兹堡VA卫生系统和成像，方法和统计（IMS）核心由UPMC PET中心和放射科的研究人员组成。有效的合作是由研究人员在ADRC和帕金森中心的研究和护理中密切合作多年的事实保证的。

DESCRIPTION (provided by applicant): The first proof-of-concept studies using the new positron emission tomography (PET) tracer, Pittsburgh compound-B (PIB), showed that PIB-PET imaging detected amyloid deposition in the brains of living AD subjects in a pattern similar to that predicted by autopsy studies. The overall objective of this proposal is to define amyloid deposition in early phases of AD and aid in the characterization of PIB as a surrogate marker of amyloid deposition by examining PIB retention and other metabolic and structural makers. The studies ask 3 major questions: 1) in normal elderly subjects, subjects with mild cognitive impairment (MCI), and mild, moderate, and severe Alzheimer's disease (AD), will deposition of PIB be detectable and correlate quantitatively with the level of severity of overall cognition, or cognitive functions referable to specific areas of the brain? 2) Will these subjects show increases in PIB retention (amount of beta amyloid) in a longitudinal study in which PIB-PET and cognitive assessments are performed annually for up to three years? 3) What is the prevalence of PIB retention across the clinical spectrum of Parkinson's Disease (PD), PD with dementia (PDD) and Dementia with Lewy Bodies (DLB); how much amyloid deposition underlies clinical dementia symptoms observed in these patients? We will also perform fluorodeoxyglucose PET (FDG-PET) and MRI to correlate metabolic and volumetric data, cognition, and PIB deposition. To accomplish these objectives we have established an Administrative Core to oversee & coordinate the projects, budgets, and data transfers; a Clinical Core to identify and assess subjects from the University of Pittsburgh ADRC and the Movement Disorders Clinics in the Department of Neurology and the Pittsburgh VA Health System and an Imaging, Methodology and Statistics (IMS) Core comprised of researchers from the UPMC PET Center and the Department of Radiology. Effective collaborations are assured by the fact that the investigators have worked together closely in research & care in the ADRC and the Parkinson's Center for many years.